Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
10 /100
LOW RISK
Score updated Aug 28, 2026

SUPN — Supernus Pharmaceuticals, Inc. Dilution Risk Tracker

Track SUPN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SUPN — Get alerts when the score changes →

As of August 28, 2026, Supernus Pharmaceuticals, Inc. (SUPN) has a DilutionWatch DilutionScore of 10/100, rated LOW dilution risk. Supernus Pharmaceuticals, Inc. has a market capitalization of $2.68B, 58.13M shares outstanding, 331 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
20
💰Cash Runway
📊 Float Risk
5
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for SUPN.
🔔 Track SUPN — Get forecast alerts →

Market Data

Market Cap$2.68B
Shares Outstanding58.13M
Float52.12M
Cash$548.17M
Debt$401.44M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 12.7% shares (2026Q1 vs prior)
331 institutional holders · 65.87M shares
#1 BlackRock, Inc. 8.80M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 4.93M shares
#3 MILLENNIUM MANAGEMENT LLC 3.32M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.82M
Days to Cover9.5
% of Float9.2%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2023-12-31
xbrl XBRL CONVERTIBLE 2022-12-31
4 INSIDER TRANSACTION 2026-03-18
4 INSIDER TRANSACTION 2026-03-16
4 INSIDER TRANSACTION 2026-03-16
Full SEC filing analysis available with free account

Recent News

No recent news

Factual SUPN Dilution Snapshot

Supernus Pharmaceuticals, Inc. (SUPN) has a DilutionScore of 10/100, rated Low dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track SUPN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SUPN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for SUPN
SUPN FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.